SWOG clinical trial number
CTSU/A011202
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Open
Phase
Abbreviated Title
Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients Who Have + Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Status Notes
ALLIANCE activated: 2/7/14
SWOG activated: 7/24/19
SWOG activated: 7/24/19
Activated
07/24/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Breast Cancer
Treatment
RT
Eligibility Criteria Expand/Collapse
Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).
Other Clinical Trials
SWOG Clinical Trial Number
S2007
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Research Committee(s)
Breast Cancer
Activated
12/15/2020
Accrual
0%
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA1131
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy
Research Committee(s)
Breast Cancer
Activated
07/24/2019
Open
Phase
SWOG Clinical Trial Number
CTSU/A011202
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Research Committee(s)
Breast Cancer
Activated
07/24/2019
Open
Phase